Unternehmen Sigilon Therapeutics, Inc.
Aktien
A3EEMR
US82657L2060
SGTX
Biotechnologie
Kurzporträt
Mitarbeiterzahl: 62
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 60 | 14.08.18 | |
Director of Finance/CFO | 58 | 01.11.19 | |
Philip Johnson
PSD | President | 59 | 11.08.23 |
Bernd Kullmann
COO | Chief Operating Officer | - | - |
Qing Sarah Yuan
CTO | Chief Tech/Sci/R&D Officer | 53 | 07.03.22 |
Chief Tech/Sci/R&D Officer | 60 | 14.06.21 | |
Chief Administrative Officer | 52 | 01.01.19 | |
Michael Thompson
BRD | Director/Board Member | - | 11.08.23 |
Robert Windsor
IRC | Investor Relations Contact | - | 01.05.21 |
Chris Anderson
SEC | Corporate Secretary | - | 11.08.23 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 60 | 14.08.18 | |
Philip Johnson
PSD | President | 59 | 11.08.23 |
Gordon Brooks
BRD | Director/Board Member | - | 11.08.23 |
Michael Thompson
BRD | Director/Board Member | - | 11.08.23 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 2 502 084 | 2 294 190 ( 91,69 %) | 0 | 91,69 % |
Unternehmenskontakt
Sektor
% 1. Jan. | Kap. | |
---|---|---|
+17.96% | 47.02 Mrd. | |
+48.77% | 41.86 Mrd. | |
+1.17% | 41.76 Mrd. | |
-4.27% | 28.8 Mrd. | |
+11.42% | 26.05 Mrd. | |
-21.39% | 19.15 Mrd. | |
+4.86% | 12.55 Mrd. | |
+27.29% | 12.34 Mrd. | |
-3.50% | 11.82 Mrd. |